Effect of cytomegalovirus (CMV) and ageing on T-bet and eomes expression on T-cell subsets by Hassouneh, Fakhri et al.
 International Journal of 
Molecular Sciences
Article
Effect of Cytomegalovirus (CMV) and Ageing on
T-Bet and Eomes Expression on T-Cell Subsets
Fakhri Hassouneh 1, Nelson Lopez-Sejas 1, Carmen Campos 1, Beatriz Sanchez-Correa 2,
Raquel Tarazona 2, Alejandra Pera 1,3,* and Rafael Solana 1,2,*
1 Immunology Unit, IMIBIC-Hospital Universitario Reina Sofia-Universidad de Cordoba, Córdoba 14004,
Spain; hassounehfakhri@yahoo.com (F.H.); nelsonj836@hotmail.com (N.L.-S.);
mccampos1977@gmail.com (C.C.)
2 Immunology Unit, Department of Physiology, University of Extremadura, Cáceres 10003, Spain;
beatrizsanchezcorrea@gmail.com (B.S.-C.); rtarazon@unex.es (R.T.)
3 Division of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton BN1 9PS, UK
* Correspondence: alejandrapera@gmail.com (A.P.); rsolana@unex.es (R.S.);
Tel.: +44-(0)-127-387-7876 (A.P.); +34-927-257-000 (ext. 51322) (R.S.)
Received: 11 May 2017; Accepted: 26 June 2017; Published: 29 June 2017
Abstract: The differential impact of ageing and cytomegalovirus (CMV) latent infection on human
T-cell subsets remains to some extent controversial. The purpose of this study was to analyse
the expression of the transcription factors T-bet and Eomes and CD57 on CD4+, CD4hiCD8lo and
CD8+ T-cell subsets in healthy individuals, stratified by age and CMV serostatus. The percentage
of CD4+ T-cells expressing T-bet or Eomes was very low, in particular in CD4+ T-cells from
young CMV-seronegative individuals, and were higher in CMV-seropositive older individuals,
in both CD57− and CD57+ CD4+ T-cells. The study of the minor peripheral blood double-positive
CD4hiCD8lo T-cells showed that the percentage of these T-cells expressing both Eomes and T-bet was
higher compared to CD4+ T-cells. The percentage of CD4hiCD8lo T-cells expressing T-bet was also
associated with CMV seropositivity and the coexpression of Eomes, T-bet and CD57 on CD4hiCD8lo
T-cells was only observed in CMV-seropositive donors, supporting the hypothesis that these cells
are mature effector memory cells. The percentage of T-cells expressing Eomes and T-bet was higher
in CD8+ T-cells than in CD4+ T-cells. The percentages of CD8+ T-cells expressing Eomes and T-bet
increased with age in CMV-seronegative and -seropositive individuals and the percentages of CD57−
CD8+ and CD57+ CD8+ T-cells coexpressing both transcription factors were similar in the different
groups studied. These results support that CMV chronic infection and/or ageing are associated
to the expansion of highly differentiated CD4+, CD4hiCD8lo and CD8+ T-cells that differentially
express T-bet and Eomes suggesting that the expression of these transcription factors is essential
for the generation and development of an effector-memory and effector T lymphocytes involved in
conferring protection against chronic CMV infection.
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1. Introduction
The ageing of the immune system, referred as immunosenescence, has been observed in both
multicellular invertebrate and vertebrate organisms, including humans [1]. As chronological age
advances, the immune system becomes less efficient at reacting against pathogens. It has been
described that situations involving chronic activation of the immune system, such as viral infections
or cancer, can induce changes in the immune system, referred as “early immunosenescence” [2–5].
Among viral infections, persistent cytomegalovirus (CMV) infection has been described to be involved
in the process of immunosenescence, contributing to the detriment of the immune response observed
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in elderly donors. Thus, it is well known that CMV infection impacts on the T-cell compartment in
ageing [6–9].
The transcription factors T-bet (T-box expressed in T-cells) and Eomesodermin (Eomes) belong to
the T-box family of transcription factors that play crucial roles in the development of different organs
and tissues including the immune system. The studies of T-bet and Eomes in the context of human
T-cells are relatively limited. In murine models T-bet was originally involved in promoting Th1 CD4+
T-cell development while inhibiting the Th2 [10] and Th17 lineage commitment [11,12]. T-bet is also
known to modulate a number of genes involved in T-cell trafficking and function [13]. Thus, high
levels of T-bet have been associated with superior cytotoxic capacity of CD8+ T-cells by upregulation of
perforin and granzyme B expression [14,15]. Although T-bet has been involved in sustaining memory
T-cells [14], it has been reported that low expression of T-bet shifts the cells into memory-like cells
impaired in sensing homeostatic signals from IL-15 [16,17].
The role of T-bet and Eomes in immune cell development and cytolytic function has been
previously described. These transcription factors are expressed in different human blood cell subsets,
including CD4+ and CD8+ T-cells, γδ T-cells, invariant natural killer (NK) T-cells, NK cells, B cells,
and dendritic cells. T-bet expression increases as peripheral cells become more differentiated [18].
Although T-bet and Eomes expression shows some overlap, their functions are not totally reciprocal.
In human peripheral blood T-cells, T-bet expression increases as cells differentiate from naive to
effector-memory and effector cells. In contrast to CD8+ T-cells, the expression of T-bet and Eomes is
very low in CD4+ T-cells. In addition, whereas the percentages of naive cells CD4 and CD8 T-cells
expressing T-bet or Eomes is very low, a high percentage of effector-memory and effector CD4 and
CD8 T-cells express these factors and the analysis of T-bet and Eomes coexpression shows that in
both CD8+ and CD4+ T-cells the majority of effector-memory and effector cells expressing high
levels of T bet (T-bethi) coexpress Eomes+ [18]. The relevance of these transcription factors in the
differentiation, development and maintenance of antiviral CD8+ T-cell responses in mice and human
is well established [19–21].
In this study, we sought to further characterize the expression of T-bet and Eomes on human
CD4 and CD8 T-cell subsets from healthy human donors in the context of ageing and CMV infection.
This analysis included the possible relationship with the expression of CD57, originally defined
as a marker of senescent T-cells and more recently considered a marker of highly differentiated
effector-memory or effector T-cells responsible of cytokine production.
2. Results
2.1. Molecular Signature of T-Cells in the Context of Ageing and CMV Infection
Multicolour flow cytometry was used to analyse the percentage of CD4+, CD4hiCD8lo, and CD8+
T-cells expressing T-bet and Eomes transcription factors, as well as in regard to CD57 expression in
those subsets (Figure 1). The analysis was carried out on cells from healthy individuals stratified by
age and CMV serostatus (Table 1). FlowJo’s Boolean analysis was used to analyse the coexpression
of T-bet and Eomes in combination with CD57. However, not all the possible Boolean combinations
contained a significant number of cells.
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Figure 1. Gating strategy used for the analysis of T-bet, Eomes and CD57 expression on T-cells.
(A) Peripheral blood lymphocytes (PBLs) were selected using forward (FSC) and side scatter (SSC)
detectors. Subsequently Live CD3+ T-cells were gated from PBLs after single cells gating, followed by
identification of CD4+, CD8+ and CD4hiCD8lo T-cells. Arrows show the sequence of the gating used,
starting from the lymphocytes gate. (B) Total expression of Eomes, T-bet and CD57 was determined
within each T-cell subset using Fluorescence minus one (FMO) controls. Figure shows a representative
example for CD4+ T-cells.
Table 1. Demographics of studied individuals (n = 25).
Group Age Group Mean Age (SD) Sex (Male/Female)
Young CMV-Seronegative Young (18–35) 31 (6.82) 5/0
Young CMV-Seropositive Young (18–35) 26 (2.92) 2/3
Middle-aged CMV-Seronegative Middle-aged (40–60) 54.2 (8.79) 3/2
Middle-aged CMV-Seropositive Middle-aged (40–60) 52.6 (5.32) 2/3
Elderly CMV-Seropositive Elderly (>65) 74.6 (10.78) 4/1
2.2. T-Bet and Eomes Expression in CD4+ T-Cells
As some CD4+ T-cells express low levels of CD8 marker and it has been shown to have a mature
phenotype distinct from CD4+CD8− T-cells, we decided to analyse both subpopulations separately.
Our data showed that although the majority of CD4+CD8− (CD4+) T-cells do not express these
transcription factors, in CMV-seropositive and aged individuals CD4+ T-cells expressing both T-bet
and Eomes are detectable. Thus, the percentage of cells expressing Eomes increased with CMV
infection in young individuals and was higher in the elderly CMV-seropositive (Figure 2, Table 2 and
Table S1). The percentage of CD4+T-bet+ T-cells on young CMV-seronegative individuals was null.
CD4+ T-cells expressing this transcription factor were higher in CMV-seropositive individuals and
older individuals, being particularly high in the older CMV-seropositive individuals.
The Boolean combination of both transcription factors in CD4+ T-cells showed that the percentage
of cells expressing Eomes but not T-bet was not significantly affected by age or CMV infection
(Figure 3A). Cells expressing only T-bet were less frequent and increased in CMV-seropositive
individuals and further increased with age. In a similar way, double-positive Eomes+ T-bet+ cells were
very low in young CMV-seronegative individuals and increased in CMV-seropositive donors with
maximum values in the elderly CMV-seropositive.
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The analysis of T-bet and Eomes according to CD57 expression on CD4+ T-cells (Figure 3B,
Table S2) showed that cells expressing both transcription factors and CD57+ are null in young
CMV-seronegative. Moreover, although very variable, the highest percentages of these cells were
found in the elderly CMV-seropositive. Indeed, CD57+CD4+ T-cells were only found in combination
with T-bet with or without Eomes. The majority of CD57−CD4+ T-cells were Eomes+T-bet−.
The percentages of these cells remained stable despite CMV infection and age. The percentage of
Eomes+CD57−CD4+ T-cells was only affected by age when coexpressing T-bet.
Table 2. Percentage of CD4+ T-cells expressing T-bet and Eomes.
Transcription Factors
Group
Young
CMV−
Young
CMV+
Middle-Aged
CMV−
Middle-Aged
CMV+
Elderly
CMV+
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
EOMES+ 3.86 0.70 8.59 2.02 5.96 2.32 7.13 1.60 13.58 3.67
T-bet+ 0.48 0.06 4.74 2.00 2.92 2.54 2.57 0.48 12.02 4.19
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Figure 2. T-bet and Eomes expression on CD4+ T-cells. (A) Dot plot graphs representative of each
group showing the expression of the studied markers on CD4+ T-cells; (B) percentage of CD4+ T-cells
expressing T-bet and Eomes on healthy individuals (n = 25), stratified by age and CMV serostatus.
Scatter plot shows the mean and SEM. Results were considered significant at * p < 0.05 and ** p < 0.01.
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studied. The percentage of T-bet+ CD4hiCD8lo T-cells was also higher than in CD4+ T-cells and 
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i no significant difference in percentage of cells, the ind vi uals with the highest numbers of these
cells were all CMV-seropositive, par cularly the elderly (Figure S1). The percentag of CD4hiCD8lo
T-cells expressing Eom was over 40% in all groups studied and noticeably h gher than those of
CD4+ T-cells (below 20%). Eomes+ CD4hiCD8lo T-cells percentage was simil r in all groups studied.
The percentage of T-bet+ CD4hiCD8lo T-cells was also higher than in CD4+ T-cells and particul rly
high in old CMV-seropositive individuals (Figure 4, Table 3).
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Analysis of the coexpression pattern of Eomes and T-bet in CD4hiCD8lo T-cell subset showed
that the majority of cells from young CMV-seronegative individuals were Eomes+ T-bet− and the
percentage of these cells were not affected by CMV infection or age. Cells expressing T-bet were
present in significant numbers in the elderly CMV-seropositive individuals, especially the Eomes+
T-bet+ cells (Figure 5A).
The analysis of T-bet and Eomes expression in regards to CD57 expression on CD4hiCD8lo T-cells
(Figure 5B, Table S2) showed that the percentage of cells expressing both transcription factors and
CD57 was very low in the young CMV-seronegative individuals and values were significantly higher
in elderly seropositive donors. CD57+ CD4hiCD8lo T-cells always coexpressed T-bet with or without
Eomes. The majority of CD57− CD4hiCD8lo T-cells were Eomes+ and were not affected by CMV
infection. CD57−Eomes+T-bet+ cells increased with age in CMV-seropositive individuals.
Table 3. Percentage of CD4hiCD8lo T-cells expressing T-bet and Eomes.
Transcription Factors
Group
Young
CMV−
Young
CMV+
Middle-Aged
CMV−
Middle-Aged
CMV+
Elderly
CMV+
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
EOMES+ 39.01 8.05 58.05 6.98 43.22 6.24 41.53 8.35 63.87 11.93
T-bet+ 7.35 1.66 33.81 14.48 17.93 12.17 26.85 7.00 51.87 13.01
Figure 4. T-bet and Eomes expression on CD4hiCD8lo T-cells. (A) Dot plot graphs show the expression
of T-bet and Eomes on CD4hiCD8lo T-cells for each group studied; (B) expression of T-bet and Eomes
on CD4hiCD8lo T-cells from healthy individuals (n = 25), stratified by age and CMV serostatus. Scatter
plot shows the mean and SEM. Results were considered significant at * p < 0.05 and ** p < 0.01.
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Figure 5. T-bet and Eomes coexpression with and without CD57 on CD4hiCD8lo T-cells from healthy
individuals (n = 25), stratified by age and CMV serostatus. (A) Coexpression of T-bet and Eomes on
CD4hiCD8lo T-cells; (B) T-bet, Eomes and CD57 Boolean combinations on CD4hiCD8lo T-cells. Scatter
plots show the mean and SEM. Th combination of markers studied is indicated in the table below the
scatter graphs. Results were considered significant at * p < 0.05 and ** p < 0.01.
2.4. T-Bet and Eomes Expression i CD8+ T-Cells
As expected, t e percentage f CD8+ T-cells expressing T-bet and Eomes was higher than in
CD4+ T-cells (Tables 3 and 4). T e fraction of CD8+ T-cells expressing whichever transcription factor
increased with age in CMV-seropositive individuals (Figure 6 and Figure S1, Table 4) Furthermore,
the percentage of CD8+ T-cells that coexpressed both Eomes and T-bet was higher with age and
reaching the highest values in the elderly CMV-seropositive individuals (Figure 7A).
The analysis according to CD57 expression (Figure 7B, Table S2) showed that the percentage of
CD8+ T-cells coexpressing Eomes and T-bet increase with age, independently of CD57 expression.
CD57+CD8+ T-cells expressed very low levels of Eomes in the absence of T-bet, although a proportion
of CD57+CD8+ T-cells expressed T-bet without expressing Eomes. CD57+ CD8+ T-cells that did not
express any of the transcription factors studied were very low or null in the elderly.
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Table 4. Percentage of CD8+ T-cells expressing T-bet and Eomes.
Transcription Factors
Group
Young
CMV−
Young
CMV+
Middle-Aged
CMV−
Middle-Aged
CMV+
Elderly
CMV+
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
EOMES+ 39.28 4.57 46.09 3.54 49.58 6.57 55.73 4.42 63.24 3.31
T-bet+ 29.60 3.18 29.28 5.91 40.43 8.46 57.30 6.17 62.64 10.51
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not observed expression of CD57 or T-bet by CD4+ T-cells. The expansion of these cells is clearly a 
hallmark of CMV infection and is further increased by age. Besides, CD4hiCD8lo T-cells have a 
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In summary, CD4+ T-cells expressing CD57 always coexpress T-bet and are only found in
CMV-seropositive individuals independently of their age. In young CMV-seronegative individuals we
did not observed expression of CD57 or T-bet by CD4+ T-cells. The expansion of these cells is clearly a
hallmark of CMV infection and is further increased by age. Besides, CD4hiCD8lo T-cells have a different
phenotype than CD4+ T-cells, which do not express CD8. This subset contains higher numbers of
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cells expressing CD57, T-bet and Eomes. These results support the hypothesis that CD4hiCD8lo cells
derive from CD4+ T-cells and are mature effector memory cells. On the other hand, the percentages of
T-bet+CD8+ and Eomes+CD8+ T-cells were similar, increased with age and where higher than those
of CD4+ T-cells. The majority of CD8+ T-cells coexpressed both transcription factors with or without
CD57. Finally, in all subsets studied CD57+ T-cells were T-bet+ with or without Eomes but never
Eomes+T-bet−.
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3. Discussion
Advances in the last decade on the processes involved in immunosenescence support the idea that
some of the accepted hallmarks of T-cell immunosenescence in humans, such as the decreased numbers
of peripheral naïve T-cells and the accumulations of memory T-cells (especially affecting the CD8+
T-cell compartment), are determined not only by the lower output of T-cells due to thymus involution
but also by the individual’s history of pathogen exposure, particularly to infection with CMV. Thus,
it is generally accepted that CMV infection is a major driving force contributing to the age-associated
deterioration of adaptive immunity [22–24]. One of these hallmarks of human immunosenescence
associated with long-term CMV infection is the oligoclonal expansion of late-stage differentiated
effector memory or effector T-cells, characterised by the downregulation of co-stimulatory molecules
such as CD27 or CD28 and the expression of markers as KLRG-1 and CD57 [25].
CMV seropositivity increases with age in all the populations studied and is influenced by
geographic, ethnic and socioeconomic factors [26] and CMV seropositivity has been associated with a
significant increased risk of all-cause mortality [27].
Several studies have contributed to defining the expression of the transcription factors T-bet
and/or Eomes in T-cells and their significance in controlling CD8+ and CD4+ T-cell functions in mice
and human. In particular these transcription factors are involved in the development and maintenance
of immune response to different pathogens [21,28].
In this study we characterise the expression of the transcription factors T-bet and Eomes in
resting peripheral blood T-cell subsets defined by the expression of CD4, CD8 and CD57, from healthy
individuals stratified according to age and CMV serostatus. Several studies have shown that T-bet
and Eomes are expressed in human peripheral blood T-cells, with a higher expression on CD8+ than
in CD4+ T-cells. In addition, whereas the percentages of naive cells CD4 and CD8 T-cells expressing
T-bet or Eomes is very low, a high percentage of effector-memory and effector CD4 and CD8 T-cells
express these factors [18].
It has been shown that human peripheral blood CD4+ T-cells are predominantly T-betloEomes−,
suggesting that in peripheral blood CD4+ T-cells T-bet and Eomes likely do not significantly
cooperate to modulate CD4+ T-cell function [18]. The levels of T-bet and Eomes are very low in
CD4 naïve CD4 T-cells, and increase as T-cells become more differentiated and those CD4 T-cells
that coexpress T-bet and Eomes show an effector or effector-memory phenotype [18]. Our results
show that the percentage of resting CD4+ T-cells expressing T-bet T-cell was undetectable in young
CMV-seronegative individuals whereas variable percentages of T-bet positive CD4+ T-cells were found
in CMV-seropositive young donors, with higher values in the CMV-seropositive elderly individuals,
supporting the relevant role of CMV in the generation of effector-memory and effector CD4+ T-cells.
The expression of Eomes is also higher in CMV-seropositive (young and old) donors compared with
CMV-seronegative young donors. Subsequently, the Boolean analysis of both transcription factors
showed that the percentage of CD4+ T-cells coexpressing Eomes and T-bet cells was very low in
young CMV-seronegative individuals and increased with CMV seropositivity in young and aged
donors. The percentage of CD4+ T-cells expressing T-bet but not Eomes was also negligible in young
CMV-seronegative individuals and increased in CMV-seropositive young, middle-aged and elderly
donors. No significant changes were found in the percentages of CD4+ T-cells expressing Eomes but
not T-bet among the groups studied.
The expression of CD57 on T-cells increases with age [29], and we have previously shown
that whereas it is virtually absent on CD4 T-cells from CMV-seronegative young individuals, its
expression is higher in CMV-seropositive donors [30]. Although CD57 was originally defined as a
marker of senescent CD4 and CD8 T-cells, it is considered a marker of a subset of highly differentiated
effector-memory and effector cells. Furthermore, in CMV-seropositive young individuals, CD57+CD4+
T-cells are polyfunctional cells and produce several cytokines, including IFNγ [30]. Since both T-bet
and Eomes are known to induce IFNγ expression and other effector functions in CD4 T-cells, we next
examined the coexpression of these factors according to the expression of CD57. As expected, no CD4
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T-cells coexpressing CD57 and T-bet are found in young CMV-seronegative individuals. The majority
of CD57+CD4+ T-cells that are found in the rest of groups studied express T-bet alone or in combination
with Eomes, and CD57 expression is negligible in T-bet negative CD4 T-cells. It has been shown that
stimulation of CD4 T-cells via TCR and CD28 results in the upregulation of T-bet in most CD4+ T-cells,
whereas Eomes is only upregulated on a subset of polyfunctional CD4+ T-cells characterised by the
expression of CD300a [31]. Since we have recently shown that CD57 is also a marker of polyfunctional
CD4+ T-cells in CMV-seropositive young donors [30] and that the expression of CD300a on CD4+
T-cells is higher in CMV-seropositive aged donors [32], these results support the relevance of CMV
infection on the expansion of effector memory and effector polyfunctional CD4+ T-cells that coexpress
T-bet and Eomes. In a similar way, it has been shown that CD57+CD4+ T-cells that produce TNF-α
and IFN-γ in response to CMV stimulation express higher levels of T-bet and Eomes when compared
with CD57−CD4+ T-cells that produce TNF-α and express lower levels of both T-bet and Eomes [33].
The recent demonstration that T-bet induction on CD4+ T-cells in response to CMV stimulation, which
correlated with proliferation and effector multifunction, allows us to differentiate lung transplant
recipients mismatched for CMV that control CMV replication from those with early relapse [34]
supports the relevance of this transcription factor in the generation and maintenance of CD4+ effector
cells able to establish effective immune control during the early stages of CMV infection.
Peripheral blood double-positive (DP) CD4+ and CD8+ T-cells constitute a minor subset of
T-cells that can be found in healthy individuals of different ages, and their percentage is increased
in inflammatory autoimmune disease. An age-dependent increase in the different DP T-cell subsets
described has been observed [35]. In particular, CD4hiCD8lo (CD8αα) cells have been shown to
be terminally differentiated effector CD4+ T-cells that acquire the alpha-chain of CD8 (for revision
see [36]). Analysis of peripheral blood CD4hiCD8lo T-cells has shown that these cells have a highly
differentiated effector-memory phenotype, expressing more CXCR3 and CD57 than CD4+CD8−
T-cells [37]. Our results show that the percentage of cells expressing both Eomes and T-bet was higher
in the CD4hiCD8lo subset than in CD4+CD8− T-cells and that the percentage of CD4hiCD8lo T-cells
expressing T-bet was associated with CMV-seropositivity. Similar to CD4+ T-cells, the coexpression
of Eomes, T-bet and CD57 on CD4hiCD8lo T-cells was mainly observed in CMV-seropositive donors.
The analysis of T-bet and Eomes on CD4hiCD8lo T-cells supports the notion that these cells represent
a subset of highly differentiated CD4+ T-cells that are significantly expanded in CMV-seropositive
elderly individuals.
We have also analysed T-bet and Eomes in CD8+ T-cells in relation to the expression of CD57. It has
been described that CD57 is expressed in a significant percentage of CD8+ T-cells that increases with
aging, in particular in CMV-seropositive donors, and has been considered a marker of dysfunctional
senescent T-cells [38–43]. However, as indicated above for CD57+CD4+ T-cells, recent analysis of its
expression in healthy young individuals supports the fact that CD57+CD8+ T-cells represent a subset
of effector-memory and effector cells that are polyfunctional cells able to produce cytokines, including
IFNγ [44].
It has also been shown that high levels of T-bet in CD8+ T-cells are associated with
long-term resilience, low expression of inhibitory receptors, and protection from exhaustion in the
experimental model of murine Lymphocytic Choriomeningitis Virus (LCMV) infection [19] and in elite
non-progressor HIV-infected patients [20]. It has been proposed that in chronic viral infection, such as
murine LCMV infection or human hepatitis C virus (HCV), CD8+ cells expressing T-bethi proliferate
in response to persisting antigen, leading to Eomeshi terminal differentiation [21] and supporting the
relevance of these transcription factors in the maintenance of antiviral CD8+ T-cells during chronic viral
infection. The analysis of T-bet and Eomes expression in CD8+ T-cells according to CMV-serostatus and
age shows that the percentage of CD8+ T-cells positive for any of the transcription factors increases from
CMV-seronegative young individuals to CMV-seropositive old donors. In particular, the percentage of
CD8+ T-cells expressing T-bet but not Eomesis is higher in middle-aged and elderly CMV-seropositive
donors compared with young CMV-seropositive individuals, whereas the percentage of those CD8+
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T-cells coexpressing T-bet and Eomes is also higher in middle-aged CMV-seronegative compared
with young CMV-seronegative donors. Higher percentages of CD8+ T-cells coexpressing T-bet and
Eomes observed in old CMV-seropositive donors are found in both CD57−CD8+ and CD57+CD8+
T-cell subsets. No changes are observed in the percentage of Eomes single-positive CD8 cells (without
T-bet) among the different groups considered. The majority of these cells do not express CD57 as
the percentage of Eomes+CD57+CD8+ T-cells is negligible. These findings are in agreement with the
recent observation showing that the majority (60–70%) of NKT-like effector CD8+ T-cells, defined
by the expression of CD56, CD57 CD45RA, CD49d and KIR/NKG2A inhibitory receptors, coexpress
Eomes and T-bet [45].
Two different subsets of CMV-specific CD8+ T-cells have been defined according to the expression
of T-bet and Eomes [28]. Those expressing high levels of T-bet and lower levels of Eomes are
the dominant populations and are highly efficient at the recognition of endogenously processed
peptide–MHC complexes, although they show a low avidity for peptide–MHC, whereas those cells
with lower levels of T-bet and high levels of Eomes represent the subdominant populations, are less
efficient in the recognition of virus-infected cells, and have high peptide-MHC avidity [28]. Studies
in mice have shown that the continuous stimulation of CMV-specific T-cells by persistent antigen
exposure is required to maintain functional effector CD8+ T-cells responsible for protection against
viral reactivation [46,47]. This sustained antigen exposure throughout life likely contributes to the
age-associated oligoclonal expansion of two different subsets of CD8+ T-cells coexpressing graded
levels of T-bet and of Eomes and reflects a balance between short-lived terminal CD57+ effector CD8+
T-cells and long-lived CD57− effector-memory CD8+ lymphocytes, characteristic of the periodic
replenishment of specific T-cells necessary to achieve lifelong CMV immunity, as has been recently
postulated for chronic infections [21,28].
The analysis of T-bet and Eomes in CD8 T-cells obtained from lung transplant recipients
mismatched for CMV serostatus showed that patients showing higher ratios of T-bet:Eomes expression
in CD8+ T-cells are able to control CMV replication versus with those with lower ratios that were
viremic relapsers. CD8+ T-cells showing high ratios of T-bet:Eomes are better responders to CMV
stimulation in terms of proliferation and, cytotoxicity and cytokine production, underscoring the
importance of the T-bet:Eomes balance, with CMV-specific proliferation a key factor driving early
T-bet expression and effector function in CD8+ T-cells during primary infection to establish immune
control during early stages of CMV chronic infection [48].
In summary, our results support the relevance of CMV and aging in the expansion of highly
differentiated CD4+ and CD8+ T-cells that differentially express T-bet and/or Eomes transcription
factors. The expansion of these cells found in CMV-seropositive elderly donors suggest that the
expression of these factors is essential not only for the development but also for the maintenance of an
adequate pool of effector-memory and effector CD4+ and CD8+ T lymphocytes required to achieve
lifelong immunity against chronic CMV infection. Further studies are required to define the impact
of CMV and ageing on the expression of T-bet and Eomes in other T-cell subpopulations, such as
the well-defined central memory, effector-memory or effector subsets, and the relevance of these
transcription factors in the differentiation process of T-cells involved in the response to viruses and
other pathogens.
4. Materials and Methods
4.1. Subjects
We studied 25 healthy donors stratified according to age and CMV serostatus (Table 1). However,
all elderly donors included in the study were CMV-seropositive, as we were not able to recruit enough
CMV-seronegative individuals given that the prevalence of CMV seropositivity in Spain in individuals
over the age of 40 years is 80% [49] and, in our geographic area (Andalusia, Spain), about 99% of
individuals over 65 years are CMV-seropositive.
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All study participants provided informed written consent and met the following exclusion criteria:
absence of diabetes, cancer, severe renal failure, severe liver disease, endocrine disorders, autoimmune
diseases, or acute infectious disease; and they were not consuming drugs whose activity is known
to modify the functions of the immune system. The ethical statement was approved by the Ethics
Committee of the Reina Sofia University Hospital of Cordoba (Spain), on 25 February 2014 (reference
number 2465). Peripheral blood from each subject was collected in lithium heparin tubes, followed
by PBMCs isolation by density gradient centrifugation using Ficoll Histopage-1077 (Sigma-Aldrich,
St. Louis, MO, USA). After isolation PBMCs were cryopreserved in FBS (Sigma-Aldrich) with 10%
DMSO (Panreac Chemistry SAU, Barcelona, Spain) until experiments were performed.
4.2. CMV Serology
CMV-specific IgG and IgM was determined by automated enzyme-linked immunosorbent assay
(ELISA) (DRG International, Mountainside, NY, USA) from plasma retrieved from all donors.
4.3. Flow Cytometry and Data Analysis
For cytometry experiments, cells were thawed in RPMI 1640 (Sigma-Aldrich) with 10% FBS (Gibco
Life Technologies, Carlsbad, CA, USA) and subsequently placed in a 96-well plate at 2 × 106 cells/mL
concentration (250 µL final volume). Cells were then washed twice with PBS (4 ◦C) and surface stained
for the following antibodies: anti-Live/Dead APC-Vio770 (LIVE/DEAD® Fixable Near-IR Dead Cell
Stain Kit, life technologies), anti-CD3 VioBlue (clone: BW264/56, MiltenyiBiotec, BergischGladbach,
Germany), anti-CD57 Biotin-Anti-Biotin-Viogreen (clone: TB03, MiltenyiBiotec), anti-CD8 APC (clone:
BW135/80, MiltenyiBiotec) and anti-CD4 PE-Vio770 (clone: M-T466, MiltenyiBiotec). Following cell
fixation and permeabilisation using the Kit FoxP3 Staining Buffer Set (MiltenyiBiotec), intracellular
staining of the transcription factors was performed according to the manufacturer’s instructions, with
the following antibodies: anti-T-bet PerCP Cy5.5 (clone: 04-46, BD Pharmingen, San Diego, CA, USA)
and anti-Eomes FITC (clone: WD1928, eBioscience, Waltham, MA, USA). All antibodies were titrated
before use.
Samples were then acquired with a nine-parameter MACsQuant instrument (MiltenyiBiotech,
BergischGladbach, Germany) and analysed with FlowJo v X 10.0.7 software (TreeStar, Portland, OR,
USA). For data analysis, lymphocytes were gated according to their size and granularity (FSC vs.
SSC), then forward scatter height (FSC-H) versus forward scatter area (FSC-A) to remove doublets.
Within the singlets gate, Live T-cells (CD3+) were gated, followed by identification of the different
T-cell subsets by confronting CD4 vs. CD8. Individual gates for T-bet+, Eomes+ and CD57+ T-cells
were gated on each of these populations based on fluorescence minus one controls. A representative
example of the gating strategy is shown in Figure 1. FlowJo’s Boolean combination gating options
were used to analyse the coexpression of T-bet and Eomes and according to CD57 expression as well.
4.4. Statistical Analysis
Data were inspected for normal distribution using the Shapiro–Wilk test. No normality was
found. The Mann–Whitney U nonparametric test was used to derive p-values for comparing data
among the specific sample pairs. All statistical tests were performed with PASW Statistics v. 18. For
graphs, GraphPad Prism (version 5.0, GraphPad Software, Inc., La Jolla, CA, USA) was used. Results
are represented as scatter plots including the mean and SEM. The median and interquartile ranges of
the coexpression analysis of the transcription factor T-bet and Eomes and CD57 on T-cell subsets is
shown in the Supplementary Materials (Tables S1 and S2).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/7/1391/s1.
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